News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
285,770 Results
Type
Article (14770)
Company Profile (307)
Press Release (270693)
Section
Business (85223)
Career Advice (225)
Deals (14083)
Drug Delivery (34)
Drug Development (53676)
Employer Resources (31)
FDA (6664)
Job Trends (5736)
News (155430)
Policy (11200)
Tag
Academia (970)
Alliances (22664)
Alzheimer's disease (888)
Approvals (6659)
Artificial intelligence (100)
Bankruptcy (102)
Best Places to Work (5248)
Biotechnology (250)
Breast cancer (162)
Cancer (1207)
Cardiovascular disease (91)
Career advice (193)
CAR-T (85)
Cell therapy (257)
Clinical research (43304)
Collaboration (442)
Compensation (214)
COVID-19 (1111)
C-suite (108)
Data (1224)
Diabetes (103)
Diagnostics (1645)
Earnings (33036)
Events (50459)
Executive appointments (354)
FDA (7191)
Funding (419)
Gene therapy (194)
GLP-1 (348)
Government (1256)
Healthcare (7157)
Infectious disease (1164)
Inflammatory bowel disease (103)
IPO (7844)
Job creations (896)
Job search strategy (183)
Layoffs (194)
Legal (1527)
Lung cancer (180)
Lymphoma (79)
Manufacturing (112)
Medical device (3164)
Medtech (3165)
Mergers & acquisitions (6503)
Metabolic disorders (304)
Neuroscience (1187)
NextGen: Class of 2025 (2167)
Non-profit (1003)
Northern California (1402)
Obesity (163)
Opinion (96)
Parkinson's disease (92)
Patents (77)
People (26106)
Phase I (14897)
Phase II (19730)
Phase III (13255)
Pipeline (499)
Postmarket research (1075)
Preclinical (6187)
Radiopharmaceuticals (213)
Rare diseases (237)
Real estate (1498)
Regulatory (9331)
Research institute (1010)
Series A (79)
Southern California (1241)
Startups (2014)
United States (11255)
Vaccines (217)
Weight loss (93)
Date
Today (45)
Last 7 days (273)
Last 30 days (1433)
Last 365 days (23262)
2025 (1257)
2024 (23249)
2023 (23965)
2022 (28885)
2021 (29684)
2020 (25360)
2019 (17777)
2018 (13062)
2017 (14941)
2016 (12864)
2015 (15488)
2014 (11123)
2013 (7977)
2012 (8064)
2011 (8229)
2010 (8002)
Location
Africa (177)
Asia (18222)
Australia (3043)
California (3198)
Canada (982)
China (260)
Colorado (115)
Connecticut (167)
Delaware (84)
Europe (40259)
Florida (356)
Georgia (96)
Illinois (215)
Indiana (89)
Japan (80)
Maryland (400)
Massachusetts (2551)
Michigan (76)
Minnesota (131)
New Jersey (844)
New York (899)
North Carolina (473)
Northern California (1402)
Ohio (102)
Pennsylvania (592)
South America (260)
Southern California (1241)
Texas (406)
Washington State (299)
285,770 Results for "g1 therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
G1 Therapeutics, Inc. announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets, Monday, July 1, 2024.
July 1, 2024
·
3 min read
Deals
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 5, 2024
G1 Therapeutics, Inc. today announced the grant of inducement stock options exercisable for 4,650 shares of G1’s common stock and 2,400 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
June 5, 2024
·
2 min read
Drug Development
G1 Therapeutics Fails Late-Stage Breast Cancer Trial, Plans ‘Targeted’ Headcount Reductions
G1 Therapeutics on Monday reported Phase III study results showing its drug Cosela did not demonstrate a statistically significant effect in overall survival in triple-negative breast cancer patients.
June 24, 2024
·
2 min read
·
Tyler Patchen
Business
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the first quarter ended March 31, 2024.
May 1, 2024
·
10 min read
Press Releases
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
December 18, 2024
·
2 min read
Bio NC
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 01, 2024
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
May 1, 2024
·
2 min read
Bio NC
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on Wednesday, May 29, at 8:30AM EDT.
May 22, 2024
·
1 min read
Business
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
G1 Therapeutics, Inc will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET.
April 17, 2024
·
1 min read
Bio NC
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET.
April 4, 2024
·
1 min read
Press Releases
Pharmacosmos Group to Acquire G1 Therapeutics
August 7, 2024
·
14 min read
1 of 28,577
Next
